The development of this innovative packaging system was in response to requests from wound care practitioners. This packaging configuration overcomes the concerns expressed by users, including excessive waste of product, inability to see the product during application and unit cost for the treatment of small chronic wounds.

In addition to the new 0.75 gram blister pack the Company will continue to offer Altrazeal® in 2 gram and 5 gram foil pouches. The launch of the 0.75 gram blister pack is designed to:

Provide a more appropriate quantity for the treatment of chronic wounds

Provide a pack that incorporates an applicator to further improve ease of use

Enable the practitioner to more easily dispense the required amount of product as the powder is visible in the transparent blister pack

Have a price point that is consistent with the hospital and wound care center reimbursement structure

Have a price point that enables greater penetration into the nursing home and long-term acute care facilities

Commenting on the launch of Altrazeal® 0.75 gram blister pack in the U.S., Kerry P. Gray, President and CEO of ULURU Inc., stated, "In the near term we see this as the largest selling pack size as the volume of product and the associated treatment cost is more appropriate for smaller chronic wounds including diabetic foot ulcers and a high percentage of venous leg ulcers. Currently, the cost of the dressing used in a wound care center is covered under a procedural code, consequently, these facilities are very cost conscious when choosing the wound dressing to be used. Likewise, with nursing homes and long term care facilities, as the cost of wound dressings are the responsibility of these centers unit, acquisition cost is the primary focus. The blister pack concept is a significant advancement in the delivery of Altrazeal® to the wound and provides a product enhancement requested by wound care professionals."

Altrazeal® is an advanced scientifically engineered material that is unique in the field of advanced wound care dressings in terms of properties and performance. It incorporates the features and benefits of the desired "ideal" wound dressing. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous leg ulcers, pressure ulcers and geriatric wounds.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex Aggregate technology and OraDisc transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.ULURUInc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the improved pack design of Altrazeal®, advantages of the blister pack, and the 0.75 gram pack becoming the largest volume pack size. These statements are subject to numerous risks and uncertainties, including but not limited to ULURU's lack of profitability, the need for additional capital to operate its business, and to risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by us with the Securities and Exchange Commission.